SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3D illustration of DNA strand surrounded alien cells, abstract health science illustration
Gene Therapy
Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.
September 17, 2024
 · 
2 min read
 · 
Annalee Armstrong
3D illustration of an antibody-drug conjugate
Antibody-drug conjugate (ADC)
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
September 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Photo of a GLP-1 injector pen on a blue background
GLP-1
GLP-1s Can Potentially Cut Cirrhosis, Related Complications in MASLD: Study
In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor agonists are 14% less likely to progress to cirrhosis.
September 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boehringer Ingelheim sign on a building/
Phase III
Boehringer Aces Phase III Pulmonary Fibrosis Trial, Plans FDA Application
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and inflammation in the lungs, met its primary endpoint in a late-stage study.
September 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Infant in the hospital wearing a ventila
RSV
Sanofi, AstraZeneca Get FDA Approval of New Manufacturing Line to Bolster US Supply of RSV Antibody
The newly approved filling line will be able to provide both 50-mg and 100-mg doses of the respiratory syncytial virus antibody Beyfortus to help meet demand ahead of the 2024/2025 RSV season.
September 17, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of Bristol Myers Squibb's office California
Phase III
BMS Finds More Than 40% Survival Rate for Melanoma Combo Therapy at 10 Years
Bristol Myers Squibb presented the positive Phase III results on its already approved Opdivo-Yervoy combo at ESMO over the weekend, while separately announcing that it was returning Immatics’ bispecific T cell engager.
September 16, 2024
 · 
1 min read
 · 
Annalee Armstrong
External view of Eli Lilly's world headquarters in Indianapolis
Approvals
Lilly Secures FDA Nod for Eczema Therapy, Eyes Launch in ‘Coming Weeks’
Friday’s approval comes after a previous rejection in October 2023 due to manufacturing concerns.
September 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: AstraZeneca building in Gothenburg/iStoc
Bladder cancer
AstraZeneca’s Perioperative Imfinzi ‘Significantly Extends Survival’ in Type of Bladder Cancer
The result comes months after an FDA advisory committee flagged the risk of potential overtreatment with perioperative regimens.

September 16, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters in West London
Lung cancer
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light for anti-TIGIT therapies after a string of failures.
September 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS